The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
Abstract
In 2001 and 2005, the BSR established and updated guidelines for the use of anti-TNF drugs in RA [1, 2]. These guidelines indicated which adult RA patients should be eligible for treatment, precautions that need to be taken in the use of anti-TNF and action that should be taken in the event of adverse effects. Previous guidelines applied to the then available anti-TNF drugs [etanercept and infliximab in 2001, and etanercept, infliximab and adalimumab (first generation anti-TNF agents) in 2005]. Due to the large volume of information now available on these agents, the BSR has produced separate guidelines on eligibility for anti-TNF treatment in RA [3]. These current guidelines cover the safety aspects of anti-TNF in RA and apply to the first generation, but also to the newly licensed second-generation anti-TNF drugs, (certolizumab pegol and golimumab). This is a rapidly changing field with new data emerging each month, so it is vital that clinicians keep up to date with this area of practice. These guidelines have incorporated information that was available to the authors at the time of their completion (November 2009). Details of the literature search and evidence base underpinning these recommendations can be found online [4]. Anti-TNF should not be initiated in the presence of serious active infections. Anti-TNF should be discontinued in the presence of serious infections, but can be recommenced once the infection has resolved. Use anti-TNF therapy with caution in patients at high infection risk after discussing the relative risks and benefits. Prior to commencing anti-TNF, all patients should be screened for mycobacterial infection (using latest national guidelines). Active mycobacterial tuberculosis infection needs to be adequately treated before starting anti-TNF. Prior to commencing anti-TNF, consideration of prophylactic anti-mycobacterial therapy (as directed by the latest national guidelines) should be given to patients with potential latent disease. All patients commenced on anti-TNF should be closely monitored for mycobacterial infection. This should continue for at least 6 months after stopping treatment. Patients on anti-TNF who develop symptoms of mycobacterial infection should receive full anti-mycobacterial chemotherapy, but may continue with their anti-TNF if clinically indicated. Patients on anti-TNF should be informed of appropriate food hygiene. Health-care professionals managing patients on anti-TNF should be aware of the risk of opportunistic infections in patients on anti-TNF. They should have a high index of suspicion for atypical and opportunistic infections and anti-TNF should be promptly stopped in suspected cases and patients should have rapid access to specialist health care for consideration of early anti-bacterial/anti-fungal treatment. If a patient on anti-TNF, or a household contact, develops primary varicella (chickenpox), and the risks from infection are perceived to be significant, the patient should be considered for varicella zoster immune globulin. Shingles should be treated conventionally. Screening for risk factors for HBV infection should be performed prior to commencing anti-TNF and HBV tests should be performed in patients with risk factors. In patients who are HBV positive, a risk:benefit assessment should be undertaken, as anti-TNF treatment may be safe if appropriate anti-viral treatment is given. Close monitoring of serum aminotransaminases and HBV DNA load during therapy should be considered in patients with HBV treated with anti-TNF and concomitant anti-viral treatment would be recommended. Patients with serological evidence of cleared past infection should have their HBV serology monitored during therapy and may require concomitant anti-viral treatment if detrimental changes develop. Screening for risk factors for HCV infection should be performed prior to commencing anti-TNF and HCV tests should be performed in patients with risk factors. Studies to date suggest that anti-TNF does not have a detrimental effect on HCV infection but anti-TNF should continue to be used only with caution in such patients. Close monitoring of serum aminotransaminases and HCV RNA during therapy should be considered in patients with HCV treated with anti-TNF. Risk factors for HIV infection should be documented prior to commencing anti-TNF and, if present, an HIV test should be done. In considering anti-TNF use in HIV positive patients, it should be borne in mind that a reasonable benefit:risk ratio for HIV patients exists if: HIV infection is controlled and patients are not severely immunosuppressed; anti-TNF is given in combination with highly active anti-retroviral therapy; and close monitoring of viral load and CD4 count is undertaken and treatment changes are made in light of results. In RA patients on anti-TNF, the potential benefit of preventing post-operative infections by stopping treatment (different surgical procedures pose different risks of infection and wound healing
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Cited by
Tande, A. J., & Patel, R. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-13 · Cited by 1,885
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
CNS Demyelination with TNF-α Blockers
Kemanetzoglou, E., & Andreadou, E. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0742-1 · Cited by 319
Minozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brézin, A. P., Chee, S. P., Davis, J. L., Ramanan, A. V., Sonoda, K.-H., Carreño, E., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.017 · Cited by 285
Metadata
- Authors
- Ding, T., Ledingham, J., Luqmani, R., Westlake, S., Hyrich, K., Lunt, M., Kiely, P., Bukhari, M., Abernethy, R., Bosworth, A., Ostor, A., Gadsby, K., McKenna, F., Finney, D., Dixey, J., Deighton, C., & on behalf of the Standards, A. A. G. W. G. O. B. C. A. C. A. B.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-12
- Volume
- 49
- Issue
- 11
- Pages
- 2217-2219
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2125169255
- Cited by
- 215
- References
- 2
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. https://app.cochat.ai/papers/10.1093/rheumatology/keq249a
- The paper
- Ding, T., Ledingham, J., Luqmani, R., Westlake, S., Hyrich, K., Lunt, M., Kiely, P., Bukhari, M., Abernethy, R., Bosworth, A., Ostor, A., Gadsby, K., McKenna, F., Finney, D., Dixey, J., Deighton, C., & on behalf of the Standards, A. A. G. W. G. O. B. C. A. C. A. B. (2010). BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology. https://doi.org/10.1093/rheumatology/keq249a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.